Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Renal Cell Cancer: early-phase trial registry
1 of 10 indexed Stage IV Renal Cell Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 1 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Stage IV Renal Cell Cancer: 10 US clinical trials tracked, 1 recruiting.
Stage IV Renal Cell Cancer is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition stage-iv-renal-cell-cancer
OPEN 1 | RECR 10% | LATE 0 | EARLY 9 | RANK #1724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Angina Pectoris (10% recruiting · 10 trials)
Stage IV Renal Cell Cancer lists 1 open slots (10% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Renal Cell Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Renal Cell Cancer is recruiting below its size-band peers.
1 of 10 indexed trials (10%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Renal Cell Cancer research.
National Cancer Institute (NCI) accounts for 3 of 10 trials (30%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Renal Cell Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 28 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Stage IV Renal Cell Cancer research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT06447103
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
NCT03092856
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
NCT01684397
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00126594
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
NCT01157091
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00112476
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
City of Hope Medical Center
NCT02944617
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
NCT01158534
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT01826877
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
NCT00019396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Renal Cell Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Renal Cell Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Renal Cell Cancer page
10 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage IV Renal Cell Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage IV Renal Cell Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Renal Cell Cancer condition card totals 10 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.